The 58% ORR in first-line PDAC is well above historical chemo benchmarks (~30-35%), suggesting potential for accelerated approval. Monitor upcoming Phase 3 readouts and any FDA breakthrough designation decisions. Despite recent insider selling, the clinical signal is strong enough to justify near-term upside.
Price Chart
Executive Summary
Revolution Medicines announced updated Phase 1/2 data for daraxonrasib in previously untreated metastatic pancreatic cancer, showing a 58% confirmed ORR in combination with chemotherapy and 47% in monotherapy, with manageable safety profiles. These results support ongoing Phase 3 trials in frontline PDAC, a high-unmet need indication with ~3% five-year survival.
Key Facts
- Daraxonrasib + GnP combination showed 58% confirmed ORR (95% CI: 41, 73) in 40 patients with metastatic PDAC
- Monotherapy arm showed 47% ORR (95% CI: 31, 64), including one complete response
- No Grade 5 treatment-related adverse events reported in either cohort
- Phase 3 RASolute 303 trial ongoing in first-line PDAC; RASolute 302 recently met PFS and OS endpoints
- Pancreatic cancer has ~3% five-year survival rate; >90% of cases harbor RAS mutations
Financial Impact
High potential value creation if Phase 3 trials confirm efficacy, given lack of effective frontline therapies in PDAC and $29B market cap
Risk Factors
- Early-phase data with immature PFS/OS; later-stage results may not confirm benefit
- Competitive landscape could shift with other RAS inhibitors in development
- High market cap reflects significant expectations; any clinical setback could trigger sharp downside
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3278575 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 16d ago | 144 | $195.92 $190.74 | ▼ −2.64% | ▼ −5.21% | $206.29 (+5.29%) |
Sep 15, 2026 17d ago | Insider Cluster | $204.86 $190.95 | ▼ −6.79% | ▼ −7.61% | $206.29 (+0.70%) |
Sep 14, 2026 17d ago | Insider Cluster | $204.86 $192.86 | ▼ −5.86% | ▼ −7.98% | $206.29 (+0.70%) |
Aug 26, 2026 5w ago | 8-K | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 26, 2026 5w ago | Press Release | $215.44 $209.23 | ▼ −2.88% | ▼ −2.76% | $206.29 (−4.25%) |
Aug 25, 2026 5w ago | Insider Cluster | $211.38 $209.87 | ▼ −0.71% | ▼ −0.18% | $206.29 (−2.41%) |
Jul 2, 2026 13w ago | Press Release | $189.24 $191.13 | ▲ +1.00% | ▲ +0.07% | $206.29 (+9.01%) |
Jul 1, 2026 13w ago | Insider Cluster | $187.51 $190.46 | ▲ +1.57% | ▲ +1.31% | $206.29 (+10.02%) |
Jun 22, 2026 14w ago | 8-K | $165.81 $192.62 | ▲ +16.17% | ▲ +16.62% | $206.29 (+24.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access